Fibrotic disorders

Fibrosis is the formation of excess fibrous connective tissue in an organ or tissue in a reparative or reactive process. This can be a reactive, benign, or pathological state. In response to injury, this is scarring, and if fibrosis arises from a single cell line, this is a fibroma. Physiologically, fibrosis acts to deposit connective tissue, which can interfere with or totally inhibit the normal architecture and function of the underlying organ or tissue.
Fibrotic disorders the progressive buildup of scar tissue can occur throughout the body: lungs, liver, heart, kidney, skin, and intestines. Cardiac and pulmonary fibrosis cause scarring in the heart and lungs; cirrhosis is scarring of the liver, and scleroderma destroys multiple systems throughout the body; all are examples of how fibrotic disease can impact various organ systems.
Fibrotic disorders are typically chronic and can often fatal. Overall, 45 % of deaths across the U.S. each year are attributes to fibrotic disorders. Many are unaware of this shocking statistic because the cause of death in these cases is end-stage organ failure. However, organ failure and ultimately death are often a result of progressive fibrosis. As of today, there is no cure.

The fibrotic disorders

These findings help to explain why fibrotic disorders disproportionately affect the elderly. Her research has been published in high-impact journals such as Nature Medicine and Science Translational Medicine and has independently validated by hundreds of studies. Today, Nox4 is considered to be among the best-validated targets for fibrotic disease. But Nox4, short for NADPH oxidase 4, is an enzyme essential in generating reactive oxygen species; a core requirement to maintain homeostasis in aerobic organisms.

Nox4 can become out of balance, particularly in aging; so which leads to oxidative stress and ultimately fibrotic disorders. “Fibrotic disease impacts millions of healthcare consumers. “With hundreds of failed clinical trials for fibrotic disease, there is a clear need for improved therapeutic strategies. Nox4 is the major cellular source of oxidant generation, and a drug targeting Nox4 would shut down oxidant production to combat oxidative stress and stop the problem at the source.”

“Louise and the Fibronox team have put the hard work in to get this company starts on the right path to success; In conclusion, adding that startups like Fibronox represent a great opportunity for inventors to expand the impact of their work as well as create new opportunities in the community as they grow. “This team is strong and ready to take this project forward.”